Taysha Gene Therapies
TSHA
NZ$4.47
Share price
0.75%
Change (1 day)
14.75%
Change (1 year)
Taysha Gene Therapies (TSHA) Fails to deliver data
Key failure to deliver metrics for Taysha Gene Therapies:
- Last SEC data release: 2025-06-30
- Last 15 days FTD volume: NZ$0.06 M
- Last 3 months FTD volume: NZ$4.36 M
- Last year FTD volume: NZ$4.36 M
A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.
Failures to deliver for Taysha Gene Therapies (TSHA) - 3 months history
Number of shares, 3 months chart
Biweekly Failures to deliver volume for Taysha Gene Therapies (TSHA) - since 2020
Volume in USD (price x number of shares), data since 2020Taysha Gene Therapies (TSHA) Failure to deliver volume, Year over Year
| Year | Volume (Price x Shares) | Change |
|---|---|---|
| 2025 | NZ$17.51 M | 314.79% |
| 2024 | NZ$4.22 M | -13.01% |
| 2023 | NZ$4.85 M | -68.08% |
| 2022 | NZ$15.2 M | 346.84% |
| 2021 | NZ$3.4 M | -30.11% |
| 2020 | NZ$4.86 M |
FTD volume in the last 3 months for similar companies or competitors
| Company | FTD volume (3 months) | FTD volume (1 year) | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | NZ$2.35 M | NZ$10.02 M | 🇺🇸 USA |